64356-57-6

Usage

Uses

Used in Pharmaceutical Research:
5-Aminonicotinamide is used as a research compound for studying the role of PARPs in DNA repair and cell death mechanisms. Its ability to inhibit PARP activity makes it a valuable tool in understanding the underlying processes of various diseases and conditions.
Used in Drug Development:
5-Aminonicotinamide is used as a lead compound in the development of new drugs targeting PARP pathways. Its potential therapeutic applications in diseases such as cancer, diabetes, and inflammatory disorders make it a promising candidate for further research and development.
Used in Anticancer Applications:
5-Aminonicotinamide is used as an anticancer agent, particularly in the development of drugs that target PARP pathways. Its ability to modulate PARP activity can potentially enhance the effectiveness of cancer treatments and improve patient outcomes.
Used in Diabetes Research and Treatment:
5-Aminonicotinamide is used in the study of diabetes and its potential role in the development of new treatments. Its ability to modulate PARP activity may contribute to the understanding of diabetes pathophysiology and the development of novel therapeutic approaches.
Used in Inflammatory Disorders Research:
5-Aminonicotinamide is used in the research of inflammatory disorders, exploring its potential role in modulating PARP activity and its implications in the development of new treatments for these conditions.
Used as an Antioxidant and Neuroprotective Agent:
5-Aminonicotinamide is investigated for its potential role as an antioxidant and neuroprotective agent. Its ability to modulate PARP activity may contribute to the development of new strategies for protecting against oxidative stress and neurodegenerative diseases.

InChI:InChI=1/C5H7N3O2S/c6-4-1-2-5(8-3-4)11(7,9)10/h1-3H,6H2,(H2,7,9,10)

Upstream product

• 98548-28-8 5-acetamino-2-pyridinesulfonamide 
• 2127-09-5 2-mercapto-5-nitropyridine 
• 27885-57-0 2-thiol-5-acetaminopyridine 
• 409112-27-2 5-acetylamino-2-pyridinesulfonyl chloride 

Relevant academic research and scientific papers

Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: Solution and X-ray crystallographic studies

5-(3-Tosylureido)pyridine-2-sulfonamide and 4-tosylureido- benzenesulfonamide (ts-SA) only differ by the substitution of a CH by a nitrogen atom, but they have very different inhibitory properties against the metalloenzyme carbonic anhydrase (CA, EC 4.2.1.1). By means of X-ray crystallography on the human CA II adducts of the two compounds these differences have been rationalized. As all sulfonamides, the two compounds bind in deprotonated form to the Zn(II) ion from the enzyme active site and their organic scaffolds extend throughout the cavity, participating in many interactions with amino acid residues and water molecules. However the pyridine derivative undergoes a tilt of the heterocyclic ring compared to the benzene analog, which leads to a very different orientation of the two scaffolds when bound to the enzyme. This tilt also leads to a clash between a carbon atom from the pyridine ring of the first inhibitor and the OH moiety of Thr200, leading to less effective inhibitory properties of the pyridine versus the benzene sulfonamide derivative. Indeed, ts-SA is a promiscuous, low nanomolar inhibitor of 7 out of 10 human (h) CA isoforms, whereas the pyridine sulfonamide is a low nanomolar inhibitor only of the tumor-associated hCA IX and XII, being less effective against other 9 isoforms. Thus, a difference of one atom (N vs CH) in two isostructural sulfonamides leads to drastic differences of activity, phenomenon understood at the atomic level through the high resolution crystallographic structure and kinetic measurements reported in the paper. Combining the tail and the ring approaches in the same chemotype leads to isoform-selective, highly effective sulfonamide CA inhibitors.